The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer

References

• Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fossa SD. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. Br J Urol 1995; 75: 26–32
   PubMedGoogle Scholar
• Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock R, Armas OA, et al. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. J Urol 1992; 148: 87–91
   PubMed Web of Science ®Google Scholar
• Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001; 91: 2196–204
   PubMed Web of Science ®Google Scholar
• Lorenzato M, Rey D, Durlach A, Bouttens D, Birembaut P, Staerman F. DNA image cytometry on biopsies can help the detection of localized Gleason 3 + 3 prostate cancers. J Urol 2004; 172: 1311–3
   PubMed Web of Science ®Google Scholar
• Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995; 153: 1015–9
   PubMed Web of Science ®Google Scholar
• Forsslund G, Esposti PL, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992; 69: 1432–9
   PubMed Web of Science ®Google Scholar
• Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg 1990; 125: 327–31
   PubMedGoogle Scholar
• Schroder F, Tribukait B, Bocking A, DeVere-White R, Koss L, Lieber M, et al. Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12–13, 1993. Scand J Urol Nephrol Suppl 1994; 162: 51–63
   PubMedGoogle Scholar
• Tribukait B. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology. Acta Oncol 1991; 30: 187–92
   PubMed Web of Science ®Google Scholar
• Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002; 167: 117–22
   PubMed Web of Science ®Google Scholar
• Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996; 14: 12–20
   PubMedGoogle Scholar
• Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results. Int J Cancer 1994; 58: 211–6
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Walther PJ, Currin SM, Vollmer RT. Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison. Am J Surg Pathol 1991; 15: 1165–70
   PubMed Web of Science ®Google Scholar
• Lundberg S, Carstensen J, Rundquist I. DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res 1987; 47: 1973–7
   PubMed Web of Science ®Google Scholar
• Kucuk O, Demirer T, Gilman-Sachs A, Taw I, Mangold M, Singh S, et al. Intratumor heterogeneity of DNA ploidy and correlations with clinical stage and histologic grade in prostate cancer. J Surg Oncol 1993; 54: 171–4
   PubMed Web of Science ®Google Scholar
• O'Malley FP, Grignon DJ, Keeney M, Kerkvliet N, McLean C. DNA heterogeneity in prostatic adenocarcinoma. A DNA flow cytometric mapping study with whole organ sections of prostate. Cancer 1993; 71: 2797–802
   PubMed Web of Science ®Google Scholar
• Sassi I, Mangili F, Sanvito F, Andreassi A, Cantaboni A. Reproducibility of FCM-DNA ploidy analysis in prostatic cancer: comparison between needle biopsy and surgical specimens. Anal Cell Pathol 1993; 5: 17–21
   PubMed Web of Science ®Google Scholar
• Häggman M, de la Torre M, Norberg M, Busch C. Preoperative histological and cytological diagnosis and DNA ploidy assessment of localized prostatic cancer. A comparison between findings in biopsies and total prostatectomy specimens. APMIS 1994; 102: 841–8
   PubMed Web of Science ®Google Scholar
• Warzynski MJ, Soechtig CE, Maatman TJ, Goldsmith LC, Grobbel MA, Carothers GG, et al. DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma–necessitating multiple site analysis. Prostate 1995; 27: 329–35
   PubMed Web of Science ®Google Scholar
• Egevad L, Engström K, Mattson S, Wester K, Busch C. Heterogeneity of DNA ploidy in prostate cancer. J Urol Pathol 1999; 10: 23–37
   Google Scholar
• Steinbeck RG, Auer GU, Zetterberg AD. Reliability and significance of DNA measurements in interphase nuclei and division figures in histological sections. Eur J Cancer 1999; 35: 787–95
   PubMed Web of Science ®Google Scholar
• Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989; 141: 341–5
   PubMed Web of Science ®Google Scholar
• Vindeløv LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323–7
   PubMedGoogle Scholar
• Jones EC, McNeal J, Bruchovsky N, de-Jong G. DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 1990; 66: 752–7
   PubMed Web of Science ®Google Scholar
• Greene DR, Taylor SR, Wheeler TM, Scardino PT. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res 1991; 51: 4084–9
   PubMed Web of Science ®Google Scholar
• Horninger W, Berger AP, Rogatsch H, Gschwendtner A, Steiner H, Niescher M, et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 2004; 58: 232–7
   PubMed Web of Science ®Google Scholar
• Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol 2002; 168: 509–13
   PubMed Web of Science ®Google Scholar
• Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538–42
   PubMed Web of Science ®Google Scholar
• McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225–33
   PubMed Web of Science ®Google Scholar
• Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000; 24: 563–9
   PubMed Web of Science ®Google Scholar
• Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395–400
   PubMed Web of Science ®Google Scholar
• Pindur A, Chakraborty S, Welch DG, Wheeler TM. DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate 1994; 25: 189–98
   PubMed Web of Science ®Google Scholar
• Falkmer UG. Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. Hum Pathol 1992; 23: 360–7
   PubMed Web of Science ®Google Scholar